Raul Rodriguez Email Address

President and Chief Executive Officer

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca| R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus - both of which have commenced Phase 2 clinical trials| and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.

Results driven professional with over 18 years of product and service delivery experience focused on international enterprise customer care, support and advocacy. Specialties: • Leading strategy to execution while focusing on process development and operational improvements • Synthesizing data and numbers into stories that capture an end-to-end experience • Evolving existing customer engagement models to the next stage of business • Collaborating with Tier 1 customers / partners to ensure seamless delivery and sales of product and service solutions • Working with sales engineers and operations / account teams as they bring new products to market • CRM, Database marketing and eMarketing •Implementation Project Management •Network Operations •Staff Support •Call Center Management •Construction (Outside Plant) •Customer Service Management •Project Management •Majors Account Management •Customer Success Management